Dynocardia in the News!

December, 2024

Dynocardia Secures $1M NSF Grant to Advance ViTrack Technology

Revolutionizing Continuous Blood Pressure Monitoring with Motion-Correction Technology

Cambridge, MA. – December 3, 2024 Dynocardia has been awarded a $1 million grant by the National Science Foundation (NSF) to enhance its innovative computer vision-based motion-artifact mitigation technology. This funding will accelerate the development of the ViTrack® continuous non-invasive blood pressure (cNIBP) monitor, enabling real-time, accurate measurements of blood pressure and vital signs in diverse environments, including ambulances, hospitals, and homes. ViTrack’s cuff-less design employs advanced optomechanical sensors and computer vision to overcome challenges posed by patient movement, setting a new standard for continuous health monitoring.

Read the full press release
October, 2024

Press Release:

Dynocardia's Direct Continuous Blood Pressure Monitoring Technology Receives Grant from NIH's Commercialization Readiness Pilot Program

CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- The National Heart, Lung, and Blood Institute (NHLBI), one of the institutes that comprise the National Institutes of Health (NIH), has awarded Dynocardia, a medical technology company that is pioneering a new modality in blood pressure (BP) monitoring, a $500,000 grant under its Commercial Readiness Pilot (CRP) Program.

Read the full press release
September, 2024

2024 Engineering for Women's Health Conference

Jordan Parker-Ashe and Victoria Gonzalez-Canalle represented Dynocardia at the 2024 Engineering for Women's Health conference hosted by Northeastern University.

Our biomedical engineers Jordan Parker-Ashe and Victoria Gonzalez-Canalle represented Dynocardia at the 2024 Engineering for Women's Health conference hosted by Northeastern University. Scientists and professionals across the life sciences, medicine, and engineering disciplines gathered to share breakthrough research and lay the groundwork for tomorrow's innovations, as well as forge new connections and learn from each other. This experience was especially meaningful, as Dynocardia is conducting ongoing clinical trials involved in maternal health.

Image
August, 2024

NIH Funding Insights with Dynocardia at #HRX2024

NIH Funding Opportunities

Dynocardia had the chance to explore NIH funding opportunities at #HRX2024. The event featured Julia Berzhanskaya from the National Heart, Lung, and Blood Institute, along with a distinguished panel: Renée Arnold (NHLBI), Ken Nelson (MedTech Advantage Fund), and Mohan Thanikachalam (Dynocardia, Inc.) – to deep dive into the federal resources and programs for startups.

Image
July, 2024

Dynocardia Advances Cuff-Less Blood Pressure Tech with PracticePoint

Dynocardia’s innovative cuff-less monitor gets a boost from PracticePoint’s advanced tech and expertise.

Dynocardia, Inc. has achieved a significant breakthrough in wearable health technology with PracticePoint’s advanced support and expertise. The collaboration has been instrumental in validating and accelerating the development of their innovative cuff-less blood pressure monitor.

Image
June, 2024

Leading Player in the Blood Pressure Monitoring Market

Dynocardia Stands Out Among Top Blood Pressure Monitoring Innovators

Dynocardia is recognized as a leading player in the blood pressure monitoring market during the forecast period from 2024–2030, with its innovative technologies making a significant impact. As the market grows rapidly, Dynocardia's advancements position it prominently among top industry contenders.

June, 2024

MIT Startup Exchange

Dynocardia highlights Advances in Digital Health at 2024 MIT Webinar

Dynocardia, Inc. was delighted to join the 2024 MIT Digital Health and Wellness webinar. Prof. Mohan Thanikachalam highlighted our latest innovations in personalized patient care using real-time data.

Image
June, 2024

Dynocardia Shines at Boston Startup Events

Dynocardia Presents at Boston’s Esteemed Startup Events

Dynocardia joined Jose Tomas Dominguez Fuenzalida of Atcama Biomaterials at Greentown Labs. Our collaboration with the 3DEXPERIENCE Lab has been fantastic, and we enjoyed insightful conversations with Jillian Friot and Sean Farrell.

Image
June, 2024

Dynocardia’s CPO, José Wong Joins PracticePoint Advisory Board

José Wong, our Chief Product Officer, has joined the PracticePoint Advisory Board at Worcester Polytechnic Institute.

Image
May, 2024

Dynocardia at DeviceTalks Boston

Dynocardia's Innovations Highlighted in DeviceTalks Boston Panel on In Silico Clinical Trials

We have been a part of an electric panel discussion with Steve Levine, David Hoganson, Ellen Roche, and Mohan Thanikachalam focusing on the entire life cycle of #InSilicoClinicalTrials : the current state of the art, challenges, and the future tapping into our perspective as researchers in academia, industry, and medical practitioners.

Image
March, 2024

Mohan Thanikachalam Elevated to Senior Member at National Academy of Inventors

Tufts Faculty Member, Mohan Thanikachalam Honored as Senior Member of the National Academy of Inventors

Mohan Thanikachalam, Research Assistant Professor of Public Health & Community Medicine at Tufts University, has been recognized as a senior member of the National Academy of Inventors. This honor highlights Thanikachalam's impactful innovations, including the PURSE-HIS Study on cardiovascular disease in South Asians, pioneering healthcare models in India, and groundbreaking technologies like the ViTrack® wearable and mobile health devices. His contributions to biomedical engineering and public health have garnered prestigious awards and are set to transform patient care.

Image
March, 2024

ViTrack’s Impact on Maternal and Child Health During Pregnancy

NIH Awards $2.3M to Study ViTrack’s Impact on Maternal and Child Health During Pregnancy

ViTrack stands out as a solution capable of providing continuous, accurate blood pressure measurements regardless of patient movement or wrist position. This is achieved through a combination of computer vision and artificial intelligence, offering an advancement over traditional monitoring methods. The device’s ability to measure blood pressure on a beat-to-beat basis without external calibration represents a novel approach in the management of pregnancy-related hypertensive disorders.

Image
November, 2023

Dynocardia at MIT Madrid Symposium

Revolutionizing Healthcare Through Cutting-Edge Research and Technology

Dynocardia have participated in the prestigious MIT Madrid Symposium, where our cutting-edge research and innovative technology took center stage. Our breakthrough solutions, designed to revolutionize healthcare, were spotlighted as we continue to push the boundaries of medical science.

MIT ILP Image
November, 2023

Dassault System's 3D Experience Lab Accelerator

Dynocardia working with Dassault System's 3D Experience Lab Accelerator

Dynocardia is happy to partner with Dassault Systèmes' 3D Experience Lab Accelerator, a renowned platform for innovation and breakthrough technologies. This collaboration empowers us to accelerate the development of our pioneering healthcare solutions, utilizing the power of Dassault's cutting-edge 3D design and simulation tools.

November, 2023

HRX 2023 Breakthrough Innovation Award

Dynocardia wins Breakthrough Innovation Award in Cardiovascular health at HRX 2023

We're honored to have won first place in the #HRX2023 Breakthrough Innovation Award in Cardiovascular Digital Health for ViTrack™. We greatly appreciate this recognition from the Heart Rhythm Society.

Image
0
Skip to Content
Dynocardia
ABOUT
APPLICATIONS
TECHNOLOGY
TEAM
CLINICAL PROGRAM
NEWS
CONTACT
Dynocardia
ABOUT
APPLICATIONS
TECHNOLOGY
TEAM
CLINICAL PROGRAM
NEWS
CONTACT
ABOUT
APPLICATIONS
TECHNOLOGY
TEAM
CLINICAL PROGRAM
NEWS
CONTACT

Wendy Wilcox, MD, Chief Women’s Health Officer, NYC Health + Hospitals

“Hypertensive disorders of pregnancy pose a growing threat to pregnant women, especially among Black patients and other patients of color who bear a disproportionate burden of maternal mortality and severe maternal morbidity. After an extensive review, the NHLBI selected ViTrack to address this challenge. We’re excited about the potential to mitigate risk among the women who rely on us for their prenatal care”